Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
NCT00319930 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2010-03-08
Summary
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
Conditions
Interventions
- DRUG
-
CNF1010 (17-AAG)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-05-31
- Completion
- 2007-05-31
Countries
- United States
Study Locations
More Related Trials
-
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
NCT01169012 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
NCT01363297 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
NCT00125827 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
NCT01212380 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786 ·Status: TERMINATED ·Phase: PHASE1
-
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01243190 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
NCT02238522 ·Status: WITHDRAWN ·Phase: PHASE1
-
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
NCT04504708 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
NCT00412243 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00577694 ·Status: TERMINATED ·Phase: PHASE1
-
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
NCT00963495 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
NCT00924443 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
NCT06021600 ·Status: TERMINATED ·Phase: PHASE1
-
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
NCT01522469 ·Status: COMPLETED ·Phase: PHASE2
-
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT05143996 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296 ·Status: TERMINATED ·Phase: PHASE2
-
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT01010568 ·Status: TERMINATED ·Phase: PHASE2
-
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
NCT07014917 ·Status: RECRUITING ·Phase: PHASE2
-
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00485966 ·Status: WITHDRAWN ·Phase: PHASE2
-
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT05581030 ·Status: RECRUITING ·Phase: PHASE1
-
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
NCT03318419 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
NCT00081822 ·Status: COMPLETED ·Phase: PHASE1
-
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
NCT01126502 ·Status: TERMINATED ·Phase: PHASE1
-
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00101296 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06708897 ·Status: RECRUITING ·Phase: PHASE1